Sarkozy, C., Chartier, L., Ribrag, V., Gressin, R., Geisler, C. H., Kluin-Nelemans, H. C., . . . Cheminant, M. Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Nature Publishing Group.
Chicago Style (17th ed.) CitationSarkozy, Clémentine, et al. Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study. Nature Publishing Group.
MLA (9th ed.) CitationSarkozy, Clémentine, et al. Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study. Nature Publishing Group.
Warning: These citations may not always be 100% accurate.